

JUBILANT GENERICS LIMITED

(CIN: U24100UP2013FLC060821)

Registered Office: 1A, Sector 16A, Institutional Area,

Noida – 201 301, Uttar Pradesh, India

Phone : +91-120-4361000

Website:

NOTICE

NOTICE is hereby given that the 10th Annual General Meeting of members of Jubilant Generics Limited will be held as under:

DAY : TUESDAY
DATE : AUGUST 29, 2023
TIME : 03:00 P.M.
VENUE : REGISTERED OFFICE, 1A, SECTOR 16A, NOIDA - 201301, UTTAR PRADESH, INDIA

to transact the following business:

ORDINARY BUSINESS

1. To consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2023 and the Reports of the Board of Directors and Auditors thereon.
2. To appoint a Director in place of Mr. Arvind Chokhany [DIN: 06668147], who retires by rotation and, being eligible, offers himself for re-appointment.
3. To consider and, if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force), M/s. Walker Chandiok & Co LLP, Chartered Accountants (ICAI Registration No.: 001076N/N500013), be and is hereby appointed as the Statutory Auditors of the Company, in place of the retiring Statutory Auditors, M/s. B S R & Co. LLP, Chartered Accountants (ICAI Registration No.: 101248W/W100022), to hold office for a term of five (5) consecutive years from the conclusion of 10th Annual General Meeting till the conclusion of 15th Annual General Meeting of the Company to be held in the year 2028, at such remuneration, as shall be fixed by the Board of Directors of the Company on the basis of recommendation received from Audit Committee.”

SPECIAL BUSINESS

4. To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (the ‘Act’) (including any statutory modification or re-enactment thereof for the

time being in force), the Appointment and Remuneration Policy of the Company and subject to such approvals, consents, permissions and sanctions of the concerned authorities as may be necessary and subject to such conditions and modifications as may be prescribed, imposed or suggested by such concerned authorities while granting such approvals, consents, permissions and sanctions and as agreed to by the Board of Directors of the Company (hereinafter referred to as the 'Board' which term shall be deemed to include any committee which the Board may have constituted or hereinafter constitute to exercise the powers conferred by this resolution), approval of the members be and is hereby accorded for the re-appointment of Mr. Jasdeepsingh Gurdeepsingh Sood [DIN: 03383578] as Whole-time Director of the Company ('WTD') for a period of three (3) years effective from May 12, 2023 and shall be liable to retire by rotation on the following terms and conditions including remuneration:

| Sr. No. | Particulars | Amount per annum (Rs. Lacs) |
|--------------|---|--------------------------------|
| 1. | Basic Salary | 69.00 |
| 2. | House Rent Allowance | 60.11 |
| 3. | Contribution to Provident Fund (As per the Rules of the Company) | 8.28 |
| 4. | Gratuity (As per the Rules of the Company) | 3.32 |
| 5. | Allowances/ Perquisites | 31.79 |
| 6. | Variable Pay [Payable as per Variable Pay Plan of the Company] | 49.63 |
| 7. | LTIP | 32.34 |
| Total | | 254.46 |

RESOLVED FURTHER THAT the Board be and is hereby authorized to vary, alter or enhance (collectively referred to as 'Variation') the remuneration payable to WTD from time to time, considering the performance of WTD, profitability of the Company and other relevant factors, during the tenure of his appointment to the extent permitted under Section 197 read with Schedule V and other applicable provisions, if any, of the Act.

RESOLVED FURTHER THAT the remuneration paid/ payable to WTD as mentioned above may exceed 5% of net profits of the Company and the aggregate remuneration paid/payable to the Managing Director(s) and Whole-time Director(s) may exceed 10% of net profits of the Company, calculated in accordance with the provisions of Section 198 of the Act or any amendment thereto and where in any financial year during the tenure of appointment of WTD, the Company has no profit or its profits are inadequate, the remuneration mentioned above (including any revision in the remuneration that may be approved by the Board of Directors from time to time) be paid as minimum remuneration to WTD.

RESOLVED FURTHER THAT the Board of the Company be and is hereby authorised to do all such acts and deeds as it may consider necessary, expedient or desirable, in order to give effect to the foregoing resolution or otherwise as considered by the Board to be in the best interest of the Company."

5. To consider and if thought fit, to pass with or without modifications, the following resolution as **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 149, 152 and other applicable provisions, if any, of the Companies Act, 2013 (the ‘Act’) and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof for the time being in force), Dr. Jaidev Sanjeev Rajpal [DIN: 09734618], who was appointed as an Additional Director of the Company effective from October 11, 2022 in terms of Section 161(1) of the Act and whose term of office would expire at this Annual General Meeting and in respect of whom the Company has received a notice in writing under Section 160 of the Act from a member proposing his candidature for the office of Director, be and is hereby appointed as a Director of the Company, be and is hereby appointed as a Director of the Company.”

6. To consider and if thought fit, to pass with or without modification(s), the following resolution as **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 (the ‘Act’) (including any statutory modification or re-enactment thereof for the time being in force), the Appointment and Remuneration Policy of the Company and subject to such approvals, consents, permissions and sanctions of the concerned authorities as may be necessary and subject to such conditions and modifications as may be prescribed, imposed or suggested by such concerned authorities while granting such approvals, consents, permissions and sanctions and as agreed to by the Board of Directors of the Company (hereinafter referred to as the ‘Board’ which term shall be deemed to include any committee which the Board may have constituted or hereinafter constitute to exercise the powers conferred by this resolution), approval of the members be and is hereby accorded to the appointment of Dr. Jaidev Sanjeev Rajpal [DIN: 09734618] Managing Director & CEO (‘MD & CEO’) of the Company for a period of 3 years effective from October 11, 2022 on the following terms and conditions including remuneration, :

I. Salary, Allowances, Perquisites and Retiral Benefits

A. Basic Salary: Rs. 1,60,00,080 per annum.

B. HRA: Rs. 96,00,048 per annum.

C. Special & Other Allowances

He will be provided a special allowance upto Rs. 12,00,000 per annum and Car Allowance upto a maximum of Rs. 85,04,392 per annum.

D. Annual Variable Pay

Performance linked Variable Pay of Rs. 2,00,00,000 shall be paid per annum at 100% of the performance achievement. Payout of the Variable Pay would be determined based on the performance parameters laid out in the Company’s Variable Pay Plan

E. Long Term Incentive Plan (‘LTIP’)

Shall be entitled to Long Term Incentive plan as per ESOP Scheme of Jubilant Pharmova Limited, ultimate holding Company as may be approved by its Nomination, Remuneration and Compensation Committee.

F. Perquisites: Telephone at residence and mobile phone shall be provided as per the rules of the Company.

G. Retirals: Provident Fund, Gratuity, etc. as per the rules of the Company.

H. Others Benefits & Amenities

a) Leave Travel Allowance as per the rules of the Company.

b) Other amenities and benefits like car reimbursement, medical reimbursement, meal and gift coupons, etc. as per the rules of the Company.

c) Personal Accident Insurance, Group Term Insurance and Mediclaim Insurance and other benefits and facilities as per the rules of the Company.

RESOLVED FURTHER THAT the Board be and is hereby authorized to vary, alter or enhance (collectively referred to as 'Variation') the remuneration payable to MD & CEO from time to time, considering the performance of MD & CEO, profitability of the Company and other relevant factors, during the tenure of his appointment to the extent permitted under Section 197 read with Schedule V and other applicable provisions, if any, of the Act.

RESOLVED FURTHER THAT the remuneration paid/ payable to MD & CEO as mentioned above may exceed 5% of net profits of the Company and the aggregate remuneration paid/payable to the Managing Director(s) and Whole-time Director(s) may exceed 10% of net profits of the Company, calculated in accordance with the provisions of Section 198 of the Act or any amendment thereto and where in any financial year during the tenure of appointment of MD & CEO, the Company has no profit or its profits are inadequate, the remuneration mentioned above (including any revision in the remuneration that may be approved by the Board of Directors from time to time) be paid as minimum remuneration to MD & CEO.

RESOLVED FURTHER THAT the Board of the Company be and is hereby authorised to do all such acts and deeds as it may consider necessary, expedient or desirable, in order to give effect to the foregoing resolution or otherwise as considered by the Board to be in the best interest of the Company."

By Order of the Board
For Jubilant Generics Limited

Noida
May 26, 2023

Director

NOTES:

1. The Explanatory Statement pursuant to Section 102 of the Companies Act, 2013, relating to the Special Businesses to be transacted at the Annual General Meeting is annexed hereto.

2. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND ON POLL, TO VOTE INSTEAD OF HIMSELF/HERSELF. A PROXY NEED NOT BE A MEMBER OF THE COMPANY.**

THE INSTRUMENT APPOINTING THE PROXY, IN ORDER TO BE EFFECTIVE, MUST BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY, DULY COMPLETED AND SIGNED, NOT LESS THAN FORTY-EIGHT HOURS BEFORE THE COMMENCEMENT OF THE MEETING. MEMBERS/ PROXIES SHOULD FILL THE ATTENDANCE SLIP FOR ATTENDING THE MEETING.

3. Corporate member intending to send its authorised representative to attend the Meeting is requested to send a certified copy of the Board Resolution authorising its representative to attend and vote on its behalf at the Meeting.
4. Information pursuant to Secretarial Standard - 2 issued by The Institute of Company Secretaries of India regarding Directors proposed to be appointed / re-appointed is annexed.
5. All the documents referred to in the Notice are open for inspection at the Registered Office of the Company on all working days between 11:00 a.m and 1:00 p.m upto the date of the AGM and also at the venue of the AGM.

By Order of the Board
For Jubilant Generics Limited

Noida
May 26, 2023

Director

ANNEXURE TO NOTICE

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013 IN RESPECT OF ITEM NOS. 4, 5 and 6

The following explanatory statement pursuant to Section 102 of the Companies Act, 2013, sets out all material facts relating to the businesses mentioned in the accompanying notice.

ITEM NO. 4

In terms of the Appointment and Remuneration Policy of the Company (the 'Policy') and pursuant to the recommendations of the Nomination and Remuneration Committee ('NRC'), the Board has approved the reappointment of Mr. Jasdeepsingh Gurdeepsingh Sood as Whole-time Director ('WTD') of the Company for a period of three (3) years effective from May 12, 2023 on the terms and conditions including remuneration set out in the Notice. This is subject to applicable provisions of the Act, the rules made thereunder and approval of the members.

Brief profile of the WTD and the disclosures prescribed under the Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India are provided in Annexure-A to the Notice.

Considering his profile and rich experience, the re-appointment of Mr. Jasdeepsingh Gurdeepsingh Sood as WTD of the Company on the terms and conditions mentioned in the Notice would be beneficial to the Company.

Memorandum setting out the terms and conditions of reappointment of WTD including remuneration is available for inspection in physical and electronic form at the Registered Office of the Company on all working days between 11:00 a.m. and 1:00 p.m. upto the date of the AGM and also at the venue of the AGM.

Mr. Jasdeepsingh Gurdeepsingh Sood, may be deemed to be concerned or interested, financially or otherwise, in the resolution no. 4. None of the other Directors, Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 4 of the Notice. The Board of Directors recommends the resolution set out at Item No. 4 of the Notice for approval of the members by way of Special Resolution.

ITEM NO. 5

The Board of Directors had, at its meeting held on September 14, 2022, appointed Dr. Jaidev Sanjeev Rajpal (DIN: 09734618) as an Additional Director of the Company, effective from October 11, 2022. Pursuant to the provisions of Section 161 of the Companies Act, 2013 (the 'Act'), Dr. Jaidev holds office upto the date of ensuing Annual General Meeting and is eligible for appointment as Director of the Company.

Notice as stipulated under Section 160 of the Act has been received from a member intending to propose the appointment of Dr. Jaidev Sanjeev Rajpal Company is in receipt of the consent to act as Director and declaration that that he is not disqualified from being appointed as Director in terms of Section 164 of the Act from Dr Jaidev Sanjeev Rajpal.

The Board considers that continued association of Dr. Jaidev Sanjeev Rajpal would be of immense benefit to the Company and it is desirable to continue to avail his services.

Dr. Jaidev Sanjeev Rajpal may be deemed to be concerned or interested in the resolution relating to his appointment. None of the other Directors or their respective relatives are concerned or interested in the resolution no. 4.

The Board commends the Ordinary Resolutions set out at Item No. 4 of the Notice for approval by the members.

ITEM NO. 6

In terms of the Appointment and Remuneration Policy of the Company (the 'Policy') and pursuant to the recommendations of the Nomination and Remuneration Committee ('NRC'), the Board had, at its meeting held on September 14, 2023 approved the appointment of Dr. Jaidev Sanjeev Rajpal as a Managing Director and CEO ('MD & CEO') of the Company for a period of three (3) years effective from October 11, 2022 on the terms and conditions including remuneration set out in the Notice. This is subject to applicable provisions of the Act, the rules made thereunder and approval of the members.

Section 197 of the Companies Act, 2013 (the 'Act'), provides that a company may pay remuneration to any one Managing Director/ Whole-time Director upto 5% of net profits as calculated under Section 198 of the Act and if there is more than one Managing Director/ Whole-time Director, the Company may pay remuneration to the Managing Directors/ Whole-time Directors upto 10% of net profits by obtaining approval of the shareholders by passing Ordinary Resolution. Remuneration in excess of 5% or 10%, as applicable, may be paid by obtaining shareholders' approval by Special Resolution. Section 197 of the Act further provides that in case of no profits or inadequate profits, a company may pay remuneration to the Managing Director/ Whole-time Director pursuant to Schedule V to the Act, subject to approval of the shareholders by Special Resolution which would be valid for a period of three (3) years.

Dr. Jaidev Sanjeev Rajpal is functioning in professional capacity and fulfills the conditions mentioned in Para (B), Part II, Section II of Schedule V to the Act. Out of abundant caution and in view of the relevant provisions of the Act relating to managerial remuneration, the Company is complying with the provisions of Section II of Part II of Schedule V to the Act which, inter alia, prescribe that in case of no profits or inadequate profits, remuneration can be paid to a managerial personnel in accordance with the provisions of Section II, subject to the condition that a Special Resolution has been passed for payment of remuneration to a managerial personnel Relevant information and disclosures prescribed for the same in Schedule V to the Act are given below:

| I. General Information | | |
|-------------------------------|----------------------------|--|
| S. No. | Particulars/Subject | Information |
| 1) | Nature of industry | The Company has been engaged in the business of development, manufacturing, distribution, sales and marketing of Dosage (formulations) Forms at its plant at |

| | | Roorkee and / or CMOs, including in-licensing, out-licensing, collaboration with CROs to ensure a robust product pipeline. The Company has India Branded Pharmaceuticals (“IBP”) business which caters to dosage formulations under its own brand name to the Indian market in different therapeutic areas including chronic specialties like Cardiology and Diabetes, and multi-specialty. | | | | | | | | | | | | | | | | |
|---|---|---|-------------|------------|-----------------|-------|---|-----------|--|----------|----------------|----------|--------------------------|------------|--------------|----------|-------------------------|------------|
| 2) | Date or expected date of commencement of commercial production | The Company was incorporated on November 25, 2013 and has already commenced its operations. | | | | | | | | | | | | | | | | |
| 3) | In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus | Not applicable | | | | | | | | | | | | | | | | |
| 4) | Financial performance based on given indicators | As per Standalone Audited Financials (₹ in Million) | | | | | | | | | | | | | | | | |
| | | <table border="1"> <thead> <tr> <th>Particulars</th> <th>FY 2022-23</th> </tr> </thead> <tbody> <tr> <td>Paid up Capital</td> <td>25.80</td> </tr> <tr> <td>Reserves excluding Revaluation Reserves</td> <td>11,885.36</td> </tr> <tr> <td>Total Revenue (including other Income)</td> <td>3,266.22</td> </tr> <tr> <td>Total Expenses</td> <td>5,990.12</td> </tr> <tr> <td>Profit/(Loss) before Tax</td> <td>(2,723.90)</td> </tr> <tr> <td>Tax Expenses</td> <td>(836.29)</td> </tr> <tr> <td>Profit/(Loss) after Tax</td> <td>(1,887.61)</td> </tr> </tbody> </table> | Particulars | FY 2022-23 | Paid up Capital | 25.80 | Reserves excluding Revaluation Reserves | 11,885.36 | Total Revenue (including other Income) | 3,266.22 | Total Expenses | 5,990.12 | Profit/(Loss) before Tax | (2,723.90) | Tax Expenses | (836.29) | Profit/(Loss) after Tax | (1,887.61) |
| Particulars | FY 2022-23 | | | | | | | | | | | | | | | | | |
| Paid up Capital | 25.80 | | | | | | | | | | | | | | | | | |
| Reserves excluding Revaluation Reserves | 11,885.36 | | | | | | | | | | | | | | | | | |
| Total Revenue (including other Income) | 3,266.22 | | | | | | | | | | | | | | | | | |
| Total Expenses | 5,990.12 | | | | | | | | | | | | | | | | | |
| Profit/(Loss) before Tax | (2,723.90) | | | | | | | | | | | | | | | | | |
| Tax Expenses | (836.29) | | | | | | | | | | | | | | | | | |
| Profit/(Loss) after Tax | (1,887.61) | | | | | | | | | | | | | | | | | |
| 5) | Foreign investments or collaborations, if any. | The Company not received any direct capital investment in the last three financial years. In normal course of business, the Company has made agreements for product development and sales. | | | | | | | | | | | | | | | | |
| II. Information about the appointee: | | | | | | | | | | | | | | | | | | |
| 1) | Background details | Dr. Jaidev Sanjeev Rajpal, 50 years, a MBBS from Grant Medical College, Mumbai and MBA from IIM, Calicut. Before joining Jubilant group he was working as Partner with McKinsey & Co advising on Life Science and Chemical Companies. He has more than 20 years of experience across McKinsey, Government of India and as a practicing clinician. Dr. Jaidev Sanjeev Rajpal has a strong record of successfully delivering several strategy, organization and business transformation projects across Life Sciences and Chemical companies. | | | | | | | | | | | | | | | | |
| 2) | Past remuneration | Not applicable | | | | | | | | | | | | | | | | |
| 3) | Recognition or awards | Not applicable | | | | | | | | | | | | | | | | |

| | | |
|--------------------------------|---|---|
| 4) | Job profile and his suitability | He has been appointed as Managing Director & CEO of the Company, for a period of three (3) years effective from October 11, 2022 and is entrusted with the overall responsibility of the Company, subject to superintendence, control and directions of the Board. Taking into consideration the qualification of Dr. Jaidev Sanjeev Rajpal as well as his varied and rich experience, it is felt that the Company would immensely benefit under his leadership and guidance. |
| 5) | Remuneration proposed | As mentioned in the resolution |
| 6) | Comparative remuneration profile with respect to industry, size of the company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin) | Having regard to the experience and skills of the appointee, the proposed remuneration is at par with industry |
| 7) | Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel or other director, if any. | Dr. Jaidev Sanjeev Rajpal is not related to the Company, or the managerial personnel or other director of the Company. |
| III. Other information: | | |
| 1) | Reasons of loss or inadequate profits | Business of the Company was impacted by pricing pressure in the US market, lower volumes due to import alert and decline in Remdesivir sales as the COVID-19 pandemic eased. The CDMO Sterile business reported lower revenues as in preceding year, it witnessed a higher one-off COVID-19 related business. |
| 2) | Steps taken or proposed to be taken for improvement | <ul style="list-style-type: none"> • Continual quality improvement initiatives and engagement with the US FDA for resolution of Import Alert at the Roorkee facility • Re-prioritise geography-mix to accelerate growth in branded markets such as India and select International markets • Continue to strengthen leadership position in select products across markets |
| 3) | Expected increase in productivity and profits in measurable terms | The Company expects that import alert shall be removed by USFDA once the Roorke plant is inspected by them in the FY 24, which shall also impact productivity. Company is making continuous efforts to improve its productivity and profitability. The Management is confident of achieving sustained revenue growth in the future. |

Considering his profile and rich experience, the appointment of Dr. Jaidev Sanjeev Rajpal as a Managing Director & CEO of the Company on the terms and conditions as mentioned in the Notice would be beneficial to the Company.

Brief profile of the Managing Director & CEO and the disclosures prescribed under the Secretarial Standard on General Meetings issued by the Institute of Company Secretaries

of India are provided in Annexure-A to the Notice.

Memorandum setting out the terms and conditions of appointment of Managing Director & CEO including remuneration is available for inspection in physical and electronic form at the Registered Office of the Company on all working days between 11:00 a.m. and 1:00 p.m. upto the date of the AGM and also at the venue of the AGM.

Dr. Jaidev Sanjeev Rajpal, may deemed to be concerned or interested, financially or otherwise, in the resolution no. 5 & 6. None of the other Directors, Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 5 & 6 of the Notice. The Board of Directors recommends the resolution set out at Item No. 5 & 6 of the Notice for approval of the members by way of Special Resolution.

ANNEXURE - A

INFORMATION PURSUANT TO SECRETARIAL STANDARD - 2 ISSUED BY THE INSTITUTE OF COMPANY SECRETARIES OF INDIA REGARDING DIRECTORS PROPOSED TO BE APPOINTED/ RE-APPOINTED

| Particulars | Mr. Arvind Chokhany | Mr. Jasdeepsingh G. Sood | Dr. Jaidev Rajpal |
|--------------------|--|---|--|
| Age (Years) | 52 | 55 | 50 |
| Qualifications | CA, ICWA | B. Pharma and Dip. in Business Adm.& Mgt. | MBBS and MBA from IIM, Calicut |
| Experience | <p>He is a Group Chief Financial Officer for Jubilant Bhartia Group and Whole-time Director for Jubilant Pharmova, leading Finance, Investor Relations, Legal, Sustainability, Governance, Digital & Information technology functions of the group companies viz., Jubilant Pharmova, Jubilant Ingrevia, Jubilant FoodWorks, Jubilant Industries and other unlisted Jubilant Group companies.</p> <p>He is a merit holder Chartered Accountant and Cost Accountant with 27 years of experience. Prior to joining Jubilant Group, he was Chief Financial Officer for infrastructure business of Tata Group for 7 years. Prior to Tata Group, he spent 18 years in Global Banking managing large global businesses in Asia & Middle East markets with Deutsche, Standard Chartered and HDFC Bank. He has significant experience in the domain of portfolio and asset/risk management, Finance operations, capital and Balance sheet management, development of digital</p> | <p>He has 33 years of experience, both in Indian and global markets. Prior to joining the Company, Mr. Sood was associated with IPCA Lab Ltd. as Sr. VP - International Market for 9 years. Mr. Sood is associated with Jubilant since August 19, 2014.</p> | <p>Prior to joining Jubilant, he was associated with McKinsey & Co. as a Partner in Life Sciences and Chemical segment. He has more than 20 years of experience across McKinsey, Government of India and as a practicing clinician. Dr. Jaidev Sanjeev Rajpal has a strong track record of successfully delivering several business strategy, organisation and business transformation projects across the Life Sciences and Chemical companies.</p> |

| Particulars | Mr. Arvind Chokhany | Mr. Jasdeepsingh G. Sood | Dr. Jaidev Rajpal |
|--|---|---|--|
| | platforms, mergers and acquisitions, for elevated return on capital, working closely with the boards and shareholders in successfully steering the investor goals through C-Suite collaboration.. | | |
| Terms and conditions of appointment or re-appointment along with details of remuneration sought to be paid | Proposed to be re-appointed as Non-executive Director, liable to retire by rotation. Currently, no remuneration is proposed to be paid. | Please refer the proposed resolution | Please refer the proposed resolution |
| Remuneration drawn during the financial year 2022-23 from the Company, if applicable | NA | Rs. 2,25,40,892 | NA |
| Date of first appointment on the Board | June 3, 2021 | May 14, 2019 | October 11, 2022 |
| Shareholding in the Company | NIL | NIL | NIL |
| Relationship with other Directors, Managers and other Key Managerial Personnel of the Company | - | - | - |
| Number of meetings of the Board attended during the financial year 2022-23 | 4 | 3 | 3 |
| Other Directorships, Membership/ Chairmanship of Committees of the other Indian companies | <p>➤ Jubilant Pharmova Limited</p> <p>Member in Board Committees of Jubilant Pharmova Limited:</p> <ol style="list-style-type: none"> Audit Committee Sustainability and CSR Committee Stakeholders Relationship Committee Risk Management Committee Re-organisation Committee Finance Committee Fund Raising Committee | Decalog Pedagogy Services Private Limited | <p><u>Directorship:</u></p> <ol style="list-style-type: none"> Jubilant Cadista Pharmaceuticals Inc. USA Jubilant Pharma UK Limited, USA Jubilant Pharma NV, Belgium Jubilant Pharmaceuticals NV, Belgium PSI Supply NV, Belgium <p><u>Membership / Chairmanship of Committees: NIL</u></p> |

JUBILANT GENERICS LIMITED

(CIN: U24100UP2013FLC060821)

Registered Office: 1A, Sector 16A, Institutional Area, Noida – 201 301, Uttar Pradesh, India

Phone : +91-120-4361000

Fax : +91-120-4234895

PROXY FORM: AGM 2023

[FORM MGT – 11]

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of member(s):

Registered Address:

E-mail ID:

Folio No. :

I/We, being the member(s) holding shares of JUBILANT GENERICS LIMITED, hereby appoint:

- 1. Name :
- Address :
- E-mail ID:
- Signature:

or failing him

- 2. Name :
- Address :
- E-mail ID:
- Signature:

or failing him

- 3. Name :
- Address :
- E-mail ID:
- Signature:

as my/ our proxy to attend and vote (on a poll) for me/ us and on my/ our behalf at the 10th Annual General Meeting of the Company, to be held on Tuesday, August 29, 2023 at 3:00 P.M. at 1A, Sector 16A, Noida - 201 301, Uttar Pradesh, India and at any adjournment thereof in respect of such resolutions as are indicated below:

| Resolution No. | Resolution(s) | Vote (Optional, see Note 4) (Please mention no. of shares) | | |
|--------------------------|--|---|---------|---------|
| | | For | Against | Abstain |
| ORDINARY BUSINESS | | | | |
| 1 | To consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2023 and the Reports of the Board of Directors and Auditors thereon. | | | |
| 2 | To appoint a Director in place of Mr. Arvind Chokhany [DIN: 06668147], who retires by rotation and, being eligible, offers himself for re-appointment. | | | |
| 3 | To appoint M/s. Walker Chandiook & Co LLP, Chartered Accountants (ICAI Registration No.: 001076N/N500013), as the Statutory Auditors of the Company | | | |
| SPECIAL BUSINESS | | | | |
| 4 | To re-appointment Mr. Jasdeepsingh Gurdeepsingh Sood [DIN: 03383578] as Whole-time Director of the Company for a period of three (3) years | | | |
| 5 | To appoint Mr. Jaidev Rajpal (09734618) as Director, who retires by rotation | | | |
| 6 | To appoint Mr. Jaidev Rajpal (09734618) as Managing Director and CEO | | | |

Signed this day of 2023

.....

Signature of proxy holder(s)

.....

(Signature of Member)

Notes:

1. This form of proxy, in order to be effective, should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the meeting.
2. A member entitled to attend and vote is entitled to appoint a proxy to attend and on poll, to vote instead of himself/ herself. A proxy need not be a member.
3. Signature of member should be across a Revenue stamp of Rs. 1.
4. It is optional to indicate your preference. If you leave the "For", "Against" or "Abstain" columns blank against any or all resolutions, your proxy will be entitled to vote in the manner as he/ she may deem appropriate.

JUBILANT GENERICS LIMITED

(CIN: U24100UP2013FLC060821)

Registered Office: 1A, Sector 16A, Institutional Area, Noida – 201 301, Uttar Pradesh, India

Phone : +91-120-4361000

Fax : +91-120-4234895

ATTENDANCE SLIP: AGM 2023

PLEASE FILL IN THIS ATTENDANCE SLIP AND HAND IT OVER AT THE ENTRANCE

Name of person attending:

Capacity: Member Proxy Authorised Representative

(Please v appropriate)

I hereby record my presence at the 10th Annual General Meeting being held on Tuesday, August 29, 2023 at 3.00 P.M. at the Registered Office of the Company.

Member's / Proxy's Signature

ROUTE MAP TO THE AGM VENUE

